This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD44 Monoclonal Antibody (156-3C11), Biotin
catalog :
MA5-13887
quantity :
500 µL
price :
US 481
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
156-3C11
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
citations: 44
Published Application/Species/Sample/DilutionReference
  • flow cytometry; human; 1:200
He Q, Luo X, Wang K, Zhou Q, Ao H, Yang Y, et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem. 2014;33:173-84 pubmed publisher
  • immunohistochemistry; human
Almendro V, Kim H, Cheng Y, Gonen M, Itzkovitz S, Argani P, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014;74:1338-48 pubmed publisher
  • immunohistochemistry; human
Wu Y, Sarkissyan M, Elshimali Y, Vadgama J. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS ONE. 2013;8:e78259 pubmed publisher
  • immunohistochemistry; human; 1:200
Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, et al. Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur J Surg Oncol. 2014;40:289-96 pubmed publisher
  • immunohistochemistry; human; 1:2000
Adamczyk A, Niemiec J, Ambicka A, Mucha Małecka A, Mituś J, Rys J. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. J Mol Histol. 2014;45:35-45 pubmed publisher
  • immunohistochemistry; human; 1:100
Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, Yamada K, et al. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci. 2013;104:1127-34 pubmed publisher
  • immunocytochemistry; human; 1:200
  • immunohistochemistry; human
Jambal P, Badtke M, Harrell J, Borges V, Post M, Sollender G, et al. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013;137:431-48 pubmed publisher
  • immunoprecipitation; human
  • immunocytochemistry; human
  • western blot; human
Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012;12:458 pubmed publisher
  • immunohistochemistry; human; 1:800
Jeong B, Liang Z, Huang S, Lim J, Kim J, Lee H. CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy. Exp Ther Med. 2012;3:811-817 pubmed
  • immunohistochemistry; human
Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Kinoshita J, et al. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Oncol Lett. 2012;3:1186-1190 pubmed
  • immunohistochemistry; human; 1:100
Kagara N, Huynh K, Kuo C, Okano H, Sim M, Elashoff D, et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol. 2012;181:257-67 pubmed publisher
  • immunohistochemistry; human; 1:800
Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, et al. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. Oncology. 2012;82:168-74 pubmed publisher
  • immunohistochemistry; human
  • western blot; human
Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012;22:259-72 pubmed publisher
  • immunocytochemistry; human
Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121:2723-35 pubmed publisher
  • immunohistochemistry; human
Demirag F, Cakir E, Alpar S, Tastepe I, Kaya S. Expression of CD44 and MMP-2: possible association with histopathological features of pleuro-pulmonary solitary fibrous tumors. Turk Patoloji Derg. 2011;27:127-33 pubmed publisher
  • immunohistochemistry; human; 1:200
Lee H, Kim J, Kim Y, Choi S, Kim S, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730-8 pubmed publisher
  • immunohistochemistry; human; 1:800
Ween M, Oehler M, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci. 2011;12:1009-29 pubmed publisher
  • flow cytometry; human
  • immunocytochemistry; human
  • immunohistochemistry; human
Anido J, Sáez Borderías A, Gonzàlez Juncà A, Rodón L, Folch G, Carmona M, et al. TGF-? Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell. 2010;18:655-68 pubmed publisher
  • immunocytochemistry; human; 1:150
Karaoz E, Okçu A, Gacar G, Sağlam O, Yuruker S, Kenar H. A comprehensive characterization study of human bone marrow mscs with an emphasis on molecular and ultrastructural properties. J Cell Physiol. 2011;226:1367-82 pubmed publisher
  • immunohistochemistry; human
Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol. 2011;19:33-40 pubmed publisher
  • immunohistochemistry; human; 1:100
Kawasaki H, Ogura H, Arai Y, Baba S, Kosugi I, Tsutsui Y, et al. Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin. Pathol Int. 2010;60:228-34 pubmed publisher
  • immunohistochemistry; human
Seegmiller A, Garcia R, Huang R, Maleki A, Karandikar N, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol. 2010;23:909-20 pubmed publisher
  • immunohistochemistry; human; 1:200
Park S, Gonen M, Kim H, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120:636-44 pubmed publisher
  • immunohistochemistry; human; 1:100
Gunia S, May M, Koch S, Dietel M, Erbersdobler A. Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameters. Pathobiology. 2009;76:286-92 pubmed publisher
  • immunohistochemistry; human
Bogusz A, Seegmiller A, Garcia R, Shang P, Ashfaq R, Chen W. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132:597-605 pubmed publisher
  • immunocytochemistry; human; 1:1000
  • western blot; human; 1:2000
Dittmer A, Hohlfeld K, Lützkendorf J, Müller L, Dittmer J. Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci. 2009;66:3053-65 pubmed publisher
  • immunohistochemistry; human
Hong S, Wen J, Bang S, Park S, Song S. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125:2323-31 pubmed publisher
  • immunohistochemistry; human; 1:100
Tanei T, Morimoto K, Shimazu K, Kim S, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234-41 pubmed publisher
  • immunohistochemistry; human; 1:100
Snyder E, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009;89:857-66 pubmed publisher
  • immunohistochemistry; human
Nakajima K, Abe T, Tanaka M, Hara Y. Periodontal tissue engineering by transplantation of multilayered sheets of phenotypically modified gingival fibroblasts. J Periodontal Res. 2008;43:681-8 pubmed publisher
  • immunohistochemistry; human; 1:800
Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger Saal S, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53 pubmed publisher
  • immunohistochemistry; human; 1:200
Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39:1096-102 pubmed publisher
  • flow cytometry; human
Paupert J, Mansat De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle. 2008;7:1047-53 pubmed
  • immunohistochemistry; human
Horwitz K, Dye W, Harrell J, Kabos P, Sartorius C. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008;105:5774-9 pubmed publisher
  • immunohistochemistry; human
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988-4002 pubmed
  • immunohistochemistry; human; 1:200
Harrell J, Dye W, Harvell D, Pinto M, Jedlicka P, Sartorius C, et al. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67:10582-91 pubmed
  • immunohistochemistry; human; 1:2000
Charafe Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121:1779-85 pubmed
  • immunocytochemistry; human
Ricciardelli C, Russell D, Ween M, Mayne K, Suwiwat S, Byers S, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem. 2007;282:10814-25 pubmed
  • immunohistochemistry; human
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615-21 pubmed
  • immunohistochemistry; human
Kuo K, Liang C, Hsiao C, Lin C, Chen C, Sheu B, et al. Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol. 2006;19:1570-7 pubmed
  • immunohistochemistry; human
Harrell J, Dye W, Allred D, Jedlicka P, Spoelstra N, Sartorius C, et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006;66:9308-15 pubmed
  • immunocytochemistry; human; 1 ug/ml
  • immunohistochemistry; human
Zhuo L, Kanamori A, Kannagi R, Itano N, Wu J, Hamaguchi M, et al. SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum. J Biol Chem. 2006;281:20303-14 pubmed
  • immunohistochemistry; human; 1:100
Lo H, Xia W, Wei Y, Ali Seyed M, Huang S, Hung M. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65:338-48 pubmed
Freedland S, Seligson D, Liu A, Pantuck A, Paik S, Horvath S, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003;55:71-80 pubmed
product information
Product Type :
Antibody
Product Name :
CD44 Monoclonal Antibody (156-3C11), Biotin
Catalog # :
MA5-13887
Quantity :
500 µL
Price :
US 481
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human, Non-human primate
Applications :
Flow Cytometry: Assay Dependent, Immunocytochemistry: 1:10-1:200, Immunofluorescence: 1:10-1:200, Immunohistochemistry (Paraffin): 1-2 µg/mL, Immunoprecipitation: 2 µg/mL, Western Blot: 1-2 µg/mL
Species :
Human, Non-human primate
Clone :
156-3C11
Isotype :
IgG2a
Storage :
4° C
Description :
CD44 cell surface antigen is a 100 kDa type 1 transmembrane glycoprotein widely expressed on human leucocytes, white matter of the brain and by some epithelial cells of the intestine and breast. Several isoforms of CD44 exist, including the predominant CD44H isoform detected in many normal tissues. CD44 is a receptor for hyaluronic acid (HA) and is involved in cell-cell interactions, cell adhesion and migration. CD44 also participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing. CD44 expression may be up-regulated upon some carcinomas, and it has been speculated that this may be related to metastatic potential. CD44 is expressed by hematopoietic, non-hematopoietic cells, epithelial tissues, and to filopodia in cultured keratinocytes. Further, bone marrow myeloid cells and memory T cells express CD44 at high levels, and peripheral B and T cells can upregulate the expression of CD44 in response to certain stimulatory events. Transcripts for the CD44 gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full-length nature of some of these variants have not been determined. Alternative splicing is the basis for the structural and functional diversity of the CD44 protein. Diseases associated with CD44 dysfunction include superficial keratitis and lichen sclerosus. CD44 also may be related to tumor metastasis formation.
Immunogen :
Stimulated human leukocytes
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: Assay Dependent, Immunocytochemistry: 1:10-1:200, Immunofluorescence: 1:10-1:200, Immunohistochemistry (Paraffin): 1-2 µg/mL, Immunoprecipitation: 2 µg/mL, Western Blot: 1-2 µg/mL
Aliases :
AU023126; AW121933; AW146109; Bovine CD44; CD44; CD44 antigen; CD44 antigen-like protein; CD44 molecule; CD44 molecule (Indian blood group); CD44 protein; CD44A; CD44-like protein; CDW44; cell surface glycoprotein CD44; Cell surface glycoprotein CD44 (hyaluronate binding protein); cell-surface glycoprotein; chondroitin sulfate proteoglycan 8; CSPG8; ECMRIII; ECMR-III; epican; Extracellular matrix receptor III; extracellular matrix receptor-III; GP90 lymphocyte homing/adhesion receptor; HCELL; hematopoietic cell E- and L-selectin ligand; heparan sulfate proteoglycan; HERMES; Hermes antigen; homing function and Indian blood group system; HUTCH-I; hyaluronan receptor; Hyaluronate receptor; IN; LHR; Ly-24; Lymphocyte antigen 24; lymphocyte surface antigen precursor CD44; MC56; MDU2; MDU3; METAA; MIC4; PGP I; Pgp1; PGP-1; PGPI; PGP-I; Phagocytic glycoprotein 1; phagocytic glycoprotein I; putative Bos taurus CD44; RHAMM; sCD 44; sCD44; soluble CD 44; soluble CD44
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA